attentin 20 mg tabletter
medice arzneimittel pütter gmbh & co. kg - dexamfetaminsulfat - tabletter - 20 mg
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
medikinet 5 mg tabletter
medice arzneimittel pütter gmbh & co. kg - methylphenidathydrochlorid - tabletter - 5 mg
medikinet cr 5 mg kapsler med modificeret udløsning, hårde
medice arzneimittel pütter gmbh & co. kg - methylphenidathydrochlorid - kapsler med modificeret udløsning, hårde - 5 mg
xydalba
abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - antibakterielle midler til systemisk brug, - behandling af akutte bakterielle hud- og hudstrukturinfektioner (absssi) hos voksne.
attentin 10 mg tabletter
medice arzneimittel pütter gmbh & co. kg - dexamfetaminsulfat - tabletter - 10 mg
attentin 5 mg tabletter
medice arzneimittel pütter gmbh & co. kg - dexamfetaminsulfat - tabletter - 5 mg
viekirax
abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, ritonavir - hepatitis c kronisk - antivirale midler til systemisk anvendelse - viekirax er indiceret i kombination med andre lægemidler til behandling af kronisk hepatitis c (chc) hos voksne. for at hepatitis c virus (hcv) genotype specifikke aktivitet.
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
audalis 10 mg filmovertrukne tabletter
medice arzneimittel pütter gmbh & co. kg - atomoxetinhydrochlorid - filmovertrukne tabletter - 10 mg